Word

AAVANTGARDE

Status

Pending

Status Code

630

Status Date

Monday, January 8, 2024

Serial Number

98346994

Mark Type

4

Filing Date

Monday, January 8, 2024

Trademark Owner History

AAVantgarde Bio Srl

Classifications

40 Pharmaceutical manufacturing and processing; biotechnological or biopharmaceutical manufacturing and processing; viral vector production; gene therapy manufacturing; pharmaceutical formulation; information, advice and consultancy services relating to the aforementioned services

5 Medical and veterinary preparations for therapeutic purposes; preparations for cell therapy; preparations for gene therapy; pharmaceuticals for the delivery of genes to cells, all for medical purposes; chemical products for use in medical science; biologic preparations for medical purposes; biologic preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for medical purposes; adeno-associated viral gene therapy preparations; pharmaceutical preparations and substances for the treatment of ocular and otological disorders; biotechnological preparations for the treatment of ocular and otological disorders; preparations for gene therapy and cell therapy for the treatment of ocular and otological disorders; genetic medicines for the treatment of ocular and otological disorders; biologic preparations for use in the treatment of ophthalmological diseases and disorders; biologic preparations for use in the treatment of blinding and deafness diseases and disorders; biologic preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders; gene therapy preparations for use in the treatment of ophthalmological diseases and disorders; gene therapy preparations for use in the treatment of blinding and deafness diseases and disorders; gene therapy preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders

44 Medical services; medical services in the field of genetic or inherited or non-infectious diseases or disorders; medical services in the field of gene therapy or genetic medicine; medical services in the field of gene therapy for ophthalmological diseases and disorders, blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, renal and kidney disorders, hepatological disorders, or nervous system disorders; gene and nucleic acid delivery or modification for therapeutic purposes; gene therapy design and delivery; advisory services relating to gene therapy; provision of a website communicating educational information relating to gene therapy or genetic medicine; advisory, consultancy and information services relating to the treatment, relief and/or prevention of eye and ear disease, single gene disorders, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders; information, advice and consultancy services relating to the aforementioned services

10 Medical and surgical apparatus and instruments; medical devices; apparatus and instruments for the administration of gene therapy products; ophthalmic surgery devices and instruments; veterinary apparatus and instruments; cannulae; needles for surgical and medical purposes; adhesive pads for medical and surgical use; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof; apparatus and instruments for performing eye surgery; ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic procedures, including surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products

42 Scientific and technological services and research or design relating thereto; industrial analysis and research services; biological, medical, preclinical and clinical research or development; gene therapy research; genetic engineering, gene editing, namely, the modification of genetic material in a living organism; genetic medicine, gene therapy and genome editing research, development, analytics, clinical trials or consultancy relating thereto; biochemical assay development and performance; diagnostics development and performance; biomarker identification, namely, detection and measurement of biological properties or molecules in the body; manufacturing analytics and manufacturing process design, development and optimisation; research and development services and clinical trials services in relation to pharmaceutical preparations and substances for the treatment of disorders relating to the eye and ear, biotechnological preparations for the treatment of disorders relating to the eye and ear, preparations for gene therapy and cell therapy for the treatment of disorders relating to the eye and ear and genetic medicines for the treatment of disorders relating to the eye and ear; information, advice and consultancy services relating to the aforementioned services

Trademark Events

Jan 8, 2024

New Application Entered

Jan 11, 2024

Teas Voluntary Amendment Received

Apr 25, 2024

New Application Office Supplied Data Entered